Company Profile

Company Overview

Founded in 2006 as a partnership program between Johnson & Johnson and The Task Force for Global Health, CWW supports global efforts to reduce the burden of STH infections in children who are most severely infected or at high-risk of infection and have limited access to safe and effective treatment. CWW is currently undergoing significant growth in the donation of me-bendazole with J&J progressively increasing its annual donation from 40 million in 2010 to an annual donation of 200 million doses. It is also expected that CWW will play a role in decision-making for the GSK donation of albendazole to treat STH in children, a donation that will reach 400 million doses a year. These donations will involve a corresponding increase in the number of countries engaged in treating STH with the donated medicines. As a result of these changes in its scope and complexity, the program is being restructured.